Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
FAQ: ASH's New Ferritin Thresholds, With Jacquelyn Powers, MD, MS
2
Topical vs Oral JAK Inhibitors in Vitiligo, With Iltefat Hamzavi, MD
3
How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD
4
Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD
5